eidas high assurance resets clinician identity for cross-border care

At a glance

What this is: This is a Crayonic analysis of EU cross-border health access rules, and the key finding is that clinician identity will need high-assurance authentication by 2032 for MyHealth@EU access.

Why it matters: It matters because hospitals, IAM teams, and identity architects will need to align authentication, credential lifecycle, and auditability with a regulatory deadline rather than a local policy choice.

By the numbers:

• From 26 March 2032 clinicians using MyHealth@EU must reach the assurance level high under eIDAS.
• The regulation applies generally from 26 March 2027.
• Patients must use eID at substantial level from 26 March 2030 and at high level from 26 March 2030 for some online requests, according to the article’s timeline.

Context

Cross-border healthcare access is now an identity assurance problem as much as a clinical interoperability problem. If a clinician authenticates into MyHealth@EU, the control question is no longer only whether the record can be reached, but whether the person reaching it can be proven to the assurance level the regulation expects.

The article’s core governance gap is the mismatch between long-lived hospital access estates and a deadline that forces stronger identity proofing, authentication, and revocation discipline. That is why the discussion sits in human IAM, not just health IT, and why assurance levels have become procurement and audit issues rather than abstract policy terms.

The practical implication is broader than one cross-border workflow. Once a health system standardises on a method that can satisfy eIDAS high, that pattern tends to become the de facto login model across the clinical environment, not just for foreign patient access.

Key questions

Q: How should hospitals prepare clinician authentication for eIDAS high assurance?

A: Hospitals should treat eIDAS high as an end-to-end identity programme, not a password upgrade. That means strong enrolment, non-exportable credentials, explicit revocation, and audit evidence that can prove which assurance level supported each access path. The safest path is to design once for the highest regulated use case and then reuse that control across clinical workflows.

Q: Why do hardware-backed credentials matter more than MFA for regulated clinical access?

A: Hardware-backed credentials matter because they make the private key difficult to copy, share, or replay from a compromised workstation. MFA can still be weak if the second factor is transferable or easily observed. For regulated clinical access, the question is not simply whether two factors exist, but whether the user alone can control them reliably over time.

Q: What breaks when clinician identity proofing and revocation are weak?

A: Weak proofing and revocation break the assurance chain, even when login technology looks strong. If the organisation cannot prove who received the credential or cannot withdraw it promptly, the scheme may fail audit scrutiny and leave stale trust in place. In regulated care, that failure is often a lifecycle problem before it is a login problem.

Q: What is the difference between eIDAS substantial and high assurance for healthcare access?

A: Substantial requires at least two authentication factors from different categories under the person’s control. High goes further by requiring resistance to duplication and tampering, and protection against capable attackers. For healthcare access, that difference usually pushes organisations away from copyable credentials and toward hardware-rooted possession with tighter identity governance.

Technical breakdown

What eIDAS assurance levels mean for clinician authentication

eIDAS assurance levels describe how confidently a relying party can trust that the person authenticating is the right person. Substantial requires at least two factors from different categories under the person’s control, while high adds resistance to duplication, tampering, and capable attackers. For clinicians, that shifts the problem from simple multifactor authentication to strong possession control, stronger enrollment, and revocation discipline. A method can be technically multifactor and still fail the high bar if it is copyable, shareable, or easily bypassed on a shared workstation. See the Digital Identity, eID and Identity Wallets Guide.

Practical implication: evaluate whether current clinician sign-in methods can survive an assurance-level assessment, not just an MFA checklist.

Why hardware-backed credentials matter for cross-border care

The article points to tamper-resistant hardware because assurance high is not satisfied by a password plus a second step that can be copied, forwarded, or reused from another device. A secure element or similar hardware root of trust makes the private key non-exportable, which materially changes the trust model. The device itself becomes part of the identity boundary, and the human owner must retain exclusive control over it throughout the session. That is why shared reader habits, shared PINs, and software-only credentials are weak fits for the stated requirement.

Practical implication: prefer non-exportable credentials for clinician access paths that must survive the high-assurance test.

Why assurance is a property of the whole identity scheme

The article is careful that eIDAS assurance is not a property of one device alone. Enrollment proofing, issuance, revocation, and scheme assessment all contribute to the assurance level. That means an authenticator that looks strong on paper can still sit inside a weak identity scheme if proofing is poor or revocation is slow. For hospitals, the control boundary is therefore the end-to-end identity lifecycle, not the badge or token by itself. The technical mistake is treating the authenticator as the whole answer when auditors and regulators will assess the scheme.

Practical implication: assess the full identity lifecycle around clinician credentials, not just the login method.

NHI Mgmt Group analysis

eIDAS high turns clinician identity into a regulated assurance problem, not a local authentication preference. The article shows that hospitals will not be able to treat cross-border access as an edge case because the same login method is likely to become the default clinical workstation standard. That collapses the old assumption that access methods can vary by workflow, and it makes assurance evidence part of the identity operating model. Practitioners should treat the deadline as an architecture decision, not a policy memo.

Hardware-backed possession is now the practical dividing line between usable and merely compliant authentication. A password plus SMS, or any shared or copyable second factor, may still authenticate a user, but it does not obviously satisfy the article’s high-assurance interpretation. The useful concept here is assurance portability: the control must work on the device, in the workflow, and under audit. Identity teams should expect procurement, endpoint, and IAM decisions to converge around that requirement.

Identity proofing and revocation are part of the control, not administrative aftercare. The article correctly points out that assurance belongs to the scheme, not the badge. That means the real governance question is whether the organisation can prove who received the credential, how it was bound to the person, and how quickly it can be withdrawn when the relationship changes. For human IAM programmes, that is a lifecycle problem disguised as an authentication problem.

Cross-border health identity is a preview of broader EU assurance convergence. Once one regulated workflow defines the acceptable level, adjacent workflows rarely stay exempt for long. The field should read this as a signal that assurance language, hardware roots of trust, and auditability are becoming common requirements for high-risk human access. IAM leaders should align their roadmaps with that trajectory, not with legacy login comfort.

From our research library:

• 92% of organisations expose NHIs to third parties, raising concerns about supply chain security, according to the Ultimate Guide to NHIs.
• Read next: Digital Identity, eID and Identity Wallets Guide

What this signals

Assurance portability: once a hospital can prove a clinician’s identity to eIDAS high, that control tends to become the default access pattern for other regulated workflows too. The programme question is therefore not whether a single border-crossing use case passes, but whether the identity estate can sustain that level of proof across the clinical workstation, the enrolment process, and the revocation chain.

The article also signals a broader shift in human IAM: assurance will be measured by evidence, not by policy aspiration. Identity teams should expect audit requests to focus on how credentials were bound to the person, how they were protected from duplication, and how the organisation can show the control was active at the moment of access, according to the Ultimate Guide to NHIs.

For practitioners

• Define an assurance-level inventory Map every clinician sign-in path to the assurance level it can actually demonstrate today, including where proofing, authentication, and revocation evidence lives.
• Remove copyable second factors from clinical access Replace shared or software-only credentials with non-exportable credentials for access paths that must survive a high-assurance audit.
• Bind credential issuance to identity proofing records Ensure the identity provider can show who was enrolled, what evidence was used, and when the credential was issued and revoked.
• Plan the 2032 migration as a workstation programme Treat the MyHealth@EU deadline as a default clinical workstation standard, not a separate border-crossing exception, so you avoid duplicate authentication estates.

Key takeaways

• The article reframes cross-border clinical access as an identity assurance issue, with eIDAS high becoming the relevant benchmark by 2032.
• The most important evidence is not the presence of MFA alone, but whether the credential is hardware-backed, non-exportable, and auditable across the full lifecycle.
• Hospitals that standardise on stronger human authentication now are more likely to meet the regulatory deadline without a second migration.

Related NHI Mgmt Group resources: Digital Identity, eID and Identity Wallets Guide · Ultimate Guide to NHIs: Key Challenges and Risks · Top 10 NHI Issues

Key terms

• eIDAS Level of Assurance: eIDAS Level of Assurance is the confidence level assigned to an electronic identity or authentication process under the EU trust framework. It tells a relying party how strongly a person’s identity was checked and authenticated. Practitioners use it to set access decisions, map assurance across services, and detect when a low-assurance login is being used for a high-risk transaction.
• Identity proofing: The process of verifying that a person is who they claim to be before granting or restoring access. In higher-risk recovery paths, proofing can include stronger evidence checks such as government ID validation or liveness-based facial verification so the assurance level matches the sensitivity of the request.
• Hardware-Based Authentication: Hardware-based authentication uses a physical device, such as a security key, to prove a user’s identity. It is designed to provide stronger resistance to phishing and credential theft than phone-based or password-only methods, while supporting repeatable use across enterprise applications.
• LifeCycle Revocation: Lifecycle revocation is the process of removing identity access when a user, contractor, service, or certificate is no longer authorised. In mature programmes it is not a single event, but a verified chain across systems, making sure old privileges disappear everywhere they were previously accepted.

Deepen your knowledge

NHI governance, agentic AI identity, and machine identity lifecycle are core topics in our NHI Foundation Level course, the industry's only accredited NHI security programme. If you are building or maturing an IAM programme, it is worth exploring.